Rank 44 • Biotech & Discovery
Absci
Operates a generative AI drug creation platform that designs optimized biologics and therapeutic antibodies in silico.
Visit website- Signal Score
- 87.9
- Total raised
- $230M
- Stage
- Public
- Founded
- 2011
- Headquarters
- Vancouver, USA
- Region
- North America
Their signal
Absci translates generative AI directly into physical biologic drugs, drastically reducing lead times for drug creation and forming lucrative validation partnerships with AstraZeneca and Merck.
Signal Score 87.9editorial estimate, see how it is built
Total raised, quality of investors and recency of the last round.
Revenue trajectory, customer count, hiring and market pull.
Peer-reviewed evidence, FDA/CE clearances and live health-system deployments.
Founder track record, clinical depth on the bench and technical leadership.
Search presence, press coverage, founder and brand reach, and how often the company shows up where buyers look.
Also in Biotech & Discovery
Figures are subjective research desk estimates compiled from public sources and refreshed daily, published as editorial commentary. Company marks are shown for identification only and imply no endorsement or affiliation. Want a correction, an update or removal? and see our corrections and removals policy.